Diagnostic Value of Free Prostate-Specific Antigen among Men with a Prostate-Specific Antigen Level of <3.0 μg per Liter

European Urology

Volumn 54, Issue 2, 2008, Pages 362-370

  Finne, Patrik ^a   Auvinen, Anssi ^b   Määttänen, Liisa ^c   Tammela, Teuvo L ^d   Ruutu, Mirja ^a   Juusela, Harri ^e   Martikainen, Paula ^d   Hakama, Matti ^b,c   Stenman, Ulf Håkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c FINNISH CANCER REGISTRY   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e JORVI HOSPITAL   (Finland)

Author keywords

Free PSA; Prostate cancer screening; Total PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY;

AGED; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 45849129076     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.10.056     Document Type: Article

References (26)

1. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246
2. Carter H.B. Prostate cancers in men with low PSA levels-must we find them?. N Engl J Med 350 (2004) 2292-2294
3. Stenman U.H., Abrahamsson P.A., Aus G., et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl (2005) 64-81
4. Stenman U.-H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 (1991) 222-226
5. Christensson A., Björk T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150 (1993) 100-105
6. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274 (1995) 1214-1220
7. Partin A.W., Catalona W.J., Southwick P.C., et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48 (1996) 55-61
8. Finne P., Finne R., Bangma C., et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 111 (2004) 310-315
9. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452-1455
10. Catalona W.J., Partin A.W., Finlay J.A., et al. Use of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54 (1999) 220-223
11. Djavan B., Zlotta A., Kratzik C., et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 54 (1999) 517-522
12. Roddam A.W., Duffy M.J., Hamdy F.C., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48 (2005) 386-399
13. Roddam A.W., Hamdy F.C., Allen N.E., et al. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. BJU Int 100 (2007) 514-517
14. Southwick P.C., Catalona W.J., Partin A.W., et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162 (1999) 1346-1351
15. Raaijmakers R., Blijenberg B.G., Finlay J.A., et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 171 (2004) 2245-2249
16. Pearson J.D., Luderer A.A., Metter E.J., et al. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology 48 (1996) 4-9
17. Stenman U.H., Hakama M., Knekt P., et al. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344 (1994) 1594-1598
18. Määttänen L., Auvinen A., Stenman U.H., et al. Three-year results of the Finnish prostate cancer screening trial. J Natl Cancer Inst 93 (2001) 552-553
19. Finne P., Stenman U.H., Määttänen L., et al. The Finnish trial of prostate cancer screening: where are we now?. BJU Int 92 Suppl 2 (2003) 22-26
20. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data (1980), John Wiley, New York
21. Aus G., Becker C., Franzén S., et al. Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol 45 (2004) 160-165
22. Aus G., Damber J.E., Khatami A., et al. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 165 (2005) 1857-1861
23. Roobol M.J., Roobol D.W., and Schroder F.H. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65 (2005) 343-346
24. Lilja H., Ulmert D., Bjork T., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 25 (2007) 431-436
25. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
26. D'Amico A.V., Chen M.H., Roehl K.A., et al. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 23 (2005) 4975-4979